

Innovative targeted therapies in NSCLC and beyond

Monday, 22 October 2018

18.30–20.00

ICM – Room 13

Messe Munich
Munich, Germany

Evolution of targeted therapies

Tony Mok (Hong Kong)

Transformational therapy – setting a new standard in *ALK+* NSCLC

Rafal Dziadziuszko (Poland)

Optimising cancer care in rare mutations

Leora Horn (USA)

Innovations in blood-based testing – the way forward

Tony Mok (Hong Kong)

Debating the future

All faculty

